

TABLE OF CONTENTS

SUMMARY.....	4
INTRODUCTION PRIVATE SUPPLY AND THE MULTIPLE GOALS OF PUBLIC INTERVENTION	9
1. EXPENDITURE PATTERNS: THE COMBINED EFFECTS OF INCOME LEVELS AND INSTITUTIONAL SETTINGS	11
1.1 A small but significant share of GDP.....	11
1.2 Consumption levels depend on income but also on institutional characteristics	12
1.3 A significant share of total health expenditure.....	13
1.4 A rapid increase of expenditure in recent years, with an impact on public finances which led to fiscal consolidation	14
2. THE MAIN FEATURES OF PHARMACEUTICAL ACTIVITY	15
2.1 The role of co-payments and physician prescription behaviour on the demand side.....	15
2.1.1 Co-payments and drug demand price elasticity	15
2.1.2 Physician prescription behaviour.....	16
2.2 RD and marketing strategies driving supply forces	17
2.2.1 The contribution and the costs of R&D	17
2.2.2 Changing production costs	19
2.3 An overview of the sector's main characteristics in OECD countries	20
2.3.1 Distribution of production and its evolution.....	20
2.3.2 International competitiveness may also be linked to regulatory policies	20
2.4 Some key features of recent developments in OECD pharmaceutical markets	21
2.4.1 The introduction of generic drugs.....	21
2.4.2 The changing structure of the distribution system.....	23
2.4.3 Corporate reaction: strategies towards more concentration and vertical integration.....	24
2.4.4 The European Dimension and the role of European Integration	26
3. THE EVOLVING ROLE OF PUBLIC POLICY	27
3.1 The regulation of demand	27
3.1.1 Defining the market: listing systems and formularies	27
3.1.2 Influencing the demand of patients.....	28
3.1.3 Policies and guidelines to influence the prescribing behaviour.....	31
3.2 The regulation of supply: price fixing and profit control	33
3.2.1 Product price fixing	33
3.2.2 Profit controls	38
3.3 Public strategies for fiscal consolidation.....	38
3.4 The search for social and economic efficiency: towards an information-based and outcome-oriented strategy	40
3.4.1 Reinventing the buyers while protecting patients.....	40
3.4.2 Rationalising payments under reference pricing.....	41
3.4.3 Fostering the use of generic drugs	42
3.4.4 Sharing the costs of RD and promoting future innovation	42
3.4.5 The contributions and limits of managed care strategies.....	44
3.4.6 Improving the cost-effectiveness of prescription and educating patients	44
CONCLUSION.....	49

REFERENCES	51
ANNEX TABLES	63
Table 1. Total and public expenditure on pharmaceuticals good as a percentage of gross domestic product (GDP) ¹	63
Table 2. Total expenditure on pharmaceutical goods as a percentage of total health expenditure ¹	64
Table 3. Total and public expenditure on pharmaceutical goods per capita ¹	65
Table 4. Non-prescription drugs, and over the counter drugs (OTC), 1996	66
Table 5. Trends in pharmaceutical production, 1970-1995, (million US \$, current exchange rates, constant 1995 dollars) ¹	67
Table 6. Exports, imports and trade on pharmaceutical goods	68
Table 7. Market share and average retail prescription price, by type of drug, 1994	69
Table 8. Listing of drugs eligible for public insurance reimbursement	70
Table 9. Drugs in hospitals	71
Table 10. Co-payments and Patient Cost-Sharing Policies in OECD Countries	72
Table 11. Guidelines for prescription	75
Table 12. Fixed budgets, direct limitations of volume and expenditure	76
Table 13. Price controls	77
Table 14. Profit controls	78
Table 15. Price freezes and cut measures in selected countries	79
Table 16. Average price differences for various types of purchasers in the pharmaceutical market	80
Table 17. Reference pricing	81
Table 18. Prescription of generics	82
Table 19. Share of US HMOs with closed formularies	83
Table 20. Reduction in the volume of wasted drugs	84
Chart 1. Total expenditure on pharmaceutical goods as a share of GDP	85
Chart 2. Total expenditure on pharmaceutical goods per capita	85
Chart 3. Public expenditure on pharmaceutical goods per capita	86
Chart 4. Link between total expenditure on pharmaceutical goods per capita and GDP per capita at current exchange rates,	87
Chart 5. Link between total expenditure on pharmaceutical goods per capita and GDP per capita at purchasing power parities	88
Chart 6. Total expenditure on pharmaceutical goods as a percentage of total expenditure on health	89
Chart 7. Public expenditure on pharmaceutical goods as a percentage of public expenditure on health	89
Chart 8. Public expenditure on pharmaceutical goods versus total expenditure on pharmaceutical goods as of public and total health expenditures, 1996	90
Chart 9. R & D expenditures and effective patent life of NMEs in the United States, 1963-89	90
Chart 10. The changing structure of company costs in the pharmaceutical industry, 1973-89	91
Chart 11. Pharmaceutical production in 1995	92
Chart 12. Net pharmaceutical trade balance, OECD countries	92
Chart 13. Exports, imports and trade over domestic market, 1996	93
Chart 14. Share of Multinational Drug Company Sales Outside Home Market	94
Chart 15. Public pharmaceuticals expenditure within total pharmaceutical expenditures	94
Chart 16. Share of GDP and public coverage for pharmaceutical consumption, 1996	95
Chart 17. Relative Price trends for pharmaceuticals	96
Chart 18. Trends in the measured growth rate of total and of public expenditures on pharmaceutical goods for selected countries, 1980-1996	97
Figure 1. How PBMs fit into the payment system for prescription drugs	98